Clinical Trial

Personalized Antisense Oligonucleotide for Participants With CHCHD10 ALS

Name: Personalized Antisense Oligonucleotide for Participants With CHCHD10 ALS — clinical trial record (NCT07095686)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Enrolling by Invitation Phase 1/2

View on ClinicalTrials.gov →

Summary

This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for individual participants with amyotrophic lateral sclerosis (ALS) due to a pathogenic variant in CHCHD10

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-07-23.

Trial Details

NCT Number	NCT07095686
Lead Sponsor	n-Lorem Foundation Collaborators: Columbia University
Conditions	Amyotrophic Lateral Sclerosis
Enrollment	9 participants
Start Date	2024-10-02
Primary Completion	2027-04 (estimated)
Study Completion	2027-04 (estimated)
Updated on ClinicalTrials.gov	2026-07-13